Publications

  1. Kang D, S Coffey C, J Smith B, Yuan Y, Shi Q, Yin J. Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS). Stat Med. 2021 Mar 26 [Epub ahead of print]
    View PubMed
  2. Walker A, Marcucci G, Yin J, Blum W, Stock W, Kohlschmidt J, Mrozek K, Carroll A, Eisfeld A, Carter T, Vij R, Stuart R, Byrd J, Bloomfield C, Stone R, Larson R. Phase III randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). accepted. Blood Advances. 2021.
  3. Wang H, Hou W, Perera A, Bettler C, Beach JR, Ding X, Li J, Denning MF, Dhanarajan A, Cotler SJ, Joyce C, Yin J, Ahmed F, Roberts LR, Qiu W. Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling. Cell Rep. 2021 Feb 23; 34 (8):108765
    View PubMed
  4. Advani AS, Larsen E, Laumann K, Luger SM, Liedtke M, Devidas M, Chen Z, Yin J, Foster MC, Claxton D, Coffan K, Tallman MS, Appelbaum FR, Erba H, Stone RM, Hunger SP, McNeer JL, Loh ML, Raetz E, Winick N, Carroll W, Larson RA, Stock W. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021 Jan 26; 5 (2):504-512
    View PubMed
  5. Krishnan MS, Rajan Kd A, Park J, Arjunan V, Garcia Marques FJ, Bermudez A, Girvan OA, Hoang NS, Yin J, Nguyen MH, Kothary N, Pitteri S, Felsher DW, Dhanasekaran R. Genomic analysis of Vascular Invasion in Hepatocellular Carcinoma (HCC) Reveals Molecular Drivers and Predictive Biomarkers. Hepatology. 2020 Nov 3 Epub 2020 Nov 03
    View PubMed
  6. Xie H, Liu J, Yin J, Ogden JR, Mahipal A, McWilliams RR, Truty MJ, Bekaii-Saab TS, Petersen GM, Jatoi A, Hubbard JM, Ma WW. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. Oncologist. 2020 Nov; 25 (11):e1681-e1690 Epub 2020 Aug 04
    View PubMed
  7. Yin J, Yuan Y. Checkerboard: a Bayesian efficacy and toxicity interval design for phase I/II dose-finding trials. J Biopharm Stat. 2020 Nov 1; 30 (6):1006-1025 Epub 2020 Sept 23
    View PubMed
  8. Gulhati P, Yin J, Pederson L, Schmoll HJ, Hoff P, Douillard JY, Hecht JR, Tournigand C, Tebbut N, Chibaudel B, Gramont A, Shi Q, Overman MJ. Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA. J Natl Cancer Inst. 2020 Nov 1; 112 (11):1127-1136
    View PubMed
  9. Carr RM, Duma N, McCleary-Wheeler AL, Almada LL, Marks DL, Graham RP, Smyrk TC, Lowe V, Borad MJ, Kim G, Johnson GB, Allred JB, Yin J, Lim VS, Bekaii-Saab T, Ma WW, Erlichman C, Adjei AA, Fernandez-Zapico ME. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. Pancreatology. 2020 Sep; 20 (6):1115-1122 Epub 2020 July 14
    View PubMed
  10. Xie H, Liu J, Ogden JR, Yin J, Jatoi A, Hubbard JM, McWilliams RR, Mahipal A, Petersen GM, Bekaii-Saab TS, Ma WW. Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Am J Clin Oncol. 2020 Aug; 43 (8):586-590
    View PubMed
  11. Salem ME, Yin J, Goldberg RM, Pederson LD, Wolmark N, Alberts SR, Taieb J, Marshall JL, Lonardi S, Yoshino T, Kerr RS, Yothers G, Grothey A, Andre T, De Gramont A, Shi Q. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. Ann Oncol. 2020 Apr; 31 (4):480-486 Epub 2020 Jan 16
    View PubMed
  12. Chintakuntlawar AV, Yin J, Foote RL, Kasperbauer JL, Rivera M, Asmus E, Garces Y, Garces NI, Janus JR, Liu M, Ma DJ, Moore EJ, Morris JC 3rd, Neben-Wittich M, Price DL, Price KA, Ryder M, Van Abel KM, Hilger C, Samb E, Bible KC. A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer. Thyroid. 2019 Nov; 29 (11):1615-1622
    View PubMed
  13. Wang F, Molina J, Satele D, Yin J, Lim VS, Adjei AA. A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors. Invest New Drugs. 2019 Aug; 37 (4):658-665 Epub 2018 Oct 31
    View PubMed
  14. Xie H, Yin J, Shah MH, Menefee ME, Bible KC, Reidy-Lagunes D, Kane MA, Quinn DI, Gandara DR, Erlichman C, Adjei AA. A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma. Invest New Drugs. 2019 Aug; 37 (4):755-762 Epub 2019 June 06
    View PubMed
  15. Boyce JM, Cooper T, Yin J, Li FY, Arbogast JW. Challenges encountered and lessons learned during a trial of an electronic hand hygiene monitoring system. Am J Infect Control. 2019 Jul 16 Epub 2019 July 16
    View PubMed
  16. Yin J, LaPlant B, Uy GL, Marcucci G, Blum W, Larson RA, Stone RM, Mandrekar SJ. Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). Blood Adv. 2019 Jun 11; 3 (11):1714-1721
    View PubMed
  17. Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Mrozek K, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM, Larson RA. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019 Apr 4; 133 (14):1548-1559 Epub 2019 Jan 18
    View PubMed
  18. Jazieh K, Molina J, Allred J, Yin J, Reid J, Goetz M, Lim VS, Kaufmann SH, Adjei A. A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. Invest New Drugs. 2019 Apr; 37 (2):307-314 Epub 2018 Aug 31
    View PubMed
  19. Ruppert AS, Yin J, Davidian M, Tsiatis AA, Byrd JC, Woyach JA, Mandrekar SJ. Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia. Ann Oncol. 2019 Apr 1; 30 (4):542-550
    View PubMed
  20. Du Y, Yin J, Sargent DJ, Mandrekar SJ. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles. J Biopharm Stat. 2019; 29 (2):271-286 Epub 2018 Nov 07
    View PubMed
  21. Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, Adams RA, Van Cutsem E, Falcone A, Tebbutt NC, Seymour MT, Diaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H, de Gramont A, Grothey A, Shi Q, Sargent DJ, Marshall JL. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. Eur J Cancer. 2018 Nov; 103:205-213 Epub 2018 Sept 27
    View PubMed
  22. Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol. 2018 May 10; 36 (14):1412-1418 Epub 2018 Mar 27
    View PubMed
  23. Mu R, Yuan Y, Xu J, Mandrekar SJ, Yin J. gBOIN: a unified model-assisted phase I trial design accounting for toxicity grades, and binary or continuous end points Journal of the Royal Statistical Society: Series C (Applied Statistics). 2018.
  24. Yin J, Qin R, Sargent DJ, Erlichman C, Shi Q. A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups. J Biopharm Stat. 2018; 28 (3):451-462 Epub 2017 June 07
    View PubMed
  25. Yin J, Paoletti X, Sargent DJ, Mandrekar SJ. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data. Clin Trials. 2017 Dec; 14 (6):611-620 Epub 2017 Aug 02
    View PubMed
  26. Azad NS, El-Khoueiry A, Yin J, Oberg AL, Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P, Jones PA, Easwaran H, Kamel I, Bahary N, Kim G, Picus J, Pitot HC, Erlichman C, Donehower R, Shen H, Laird PW, Piekarz R, Baylin S, Ahuja N. Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study. Oncotarget. 2017 May 23; 8 (21):35326-35338
    View PubMed
  27. Yin J, Qin R, Ezzalfani M, Sargent DJ, Mandrekar SJ. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles. Stat Med. 2017 Jan 15; 36 (1):67-80 Epub 2016 Sept 15
    View PubMed
  28. Yin J, Shen S. Challenges and Innovations in Phase I Dose-Finding Designs for Molecularly Targeted Agents and Cancer Immunotherapies. J Biom Biostat. 2016 Dec; 7 (4) Epub 2016 Nov 14
    View PubMed
  29. Anand A, Bues M, Rule WG, Keole SR, Beltran CJ, Yin J, Haddock MG, Hallemeier CL, Miller RC, Ashman JB. Scanning proton beam therapy reduces normal tissue exposure in pelvic radiotherapy for anal cancer. Radiother Oncol. 2015 Dec; 117 (3):505-8 Epub 2015 Nov 17
    View PubMed
  30. Yin J, Reisinger HS, Weg MV, Schweizer ML, Jesson A, Morgan DJ, Forrest G, Graham M, Pineles L, Perencevich EN. Establishing evidence-based criteria for directly observed hand hygiene compliance monitoring programs (in press). Infection Control.2014;
    View PubMed
  31. Ohl M, Sissel J, Yin J, Neil B, Kaboli P. Mixed-Methods Evaluation of a Teleheath Collaborative Care Program for Persons with HIV Infection in a Rural Setting. Journal of General Internal Medicine.2013, 1-9;
    View PubMed
  32. Reisinger HS, Yin J, Radonovich L, Knighton VT, Martinello RA, Hodgson MJ, Perencevich EN. Comprehensive survey of hand hygiene measurement and improvement practices in the Veterans Health Administration. American Journal of Infection Control.2013;41:(11):989-993.
    View PubMed
  33. Yin J, Schweizer ML, Herwaldt AL, Pottinger JM, Perencevich EN. Benefits of Universal Gloving in Preventing Hospital-acquired Infections in Pediatric Units. Pediatrics.2013;131:(5):e1515-e1520.
    View PubMed
  34. Li Y, Cai X, Yin J, Glance LG, Mukamel DB. Is Higher Volume of Postacute Care Patients Associated With a Lower Rehospitalization Rate in Skilled Nursing Facilities? Med Care Res Rev.2012;69:(1):103-18.
    View PubMed
  35. Li Y, Glance LG, Yin J, Mukamel DB. Racial Disparities in Rehospitalization Among Medicare Patients in Skilled Nursing Facilities. Am J Public Health.2011;101:(5):875-882.
    View PubMed
  36. Li Y, Yin J, Cai X, Temkin-Greener H, Mukamel DB. Association of race and sites of care with pressure ulcers in high-risk nursing home residents. JAMA.2011;306:(2):179-186.
    View PubMed